While the oncology field moves toward NGS panel testing, the drugmaker has launched a program subsidizing single-gene testing for advanced melanoma patients.
The diagnostic can now be used to identify patients with esophageal squamous cell carcinoma who may benefit from first-line treatment with Keytruda.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.
Investigators used gene panel testing to assess hereditary breast and ovarian cancer risk in African American women with breast cancer, uncovering potential gaps in test access.
NEC said the deal will bolster its cancer immunotherapy development programs, which are focused on ovarian cancer and head and neck cancer.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
A finding that not all BRCA-mutated tumors are likely to respond to PARP inhibitors should make doctors more cautious when prescribing them off label.
The draft guidance recommends access to the drug through the Cancer Drugs Fund as maintenance therapy of advanced ovarian, fallopian tube, or primary peritoneal cancer.
The recommendation is based on a study in which NSCLC patients without EGFR mutations or ALK rearrangements lived longer on the combo than just on chemo.
At a real-world data workshop, Wendy Rubinstein said that labs have a responsibility under the 21st Century Cures Act to facilitate integration of genomic data into EHRs.
Investigators pooled older and new data from the Prospective Lynch Syndrome Database, tracking outcomes for different mutations across age and gender groups.
The study will explore the ability of the imaging agent to visualize and quantify CD8 T cells in metastatic cancer patients at baseline and after receiving immunotherapies.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
The software firm will use NGS data from patient biopsies to create molecular profiles and offer individualized cancer treatment recommendations.
Though some experts prefer the comprehensive nature of whole-genome sequencing, others find whole-exome sequencing or targeted exome panels to be more useful.
Labs in China can now use the Cobas EGFR Mutation Test v2 with either tissue or plasma samples as a CDx for three Roche oncology drugs in NSCLC patients.
The partners will glean real-world evidence from Syapse's network of health system partners with the aim of informing precision oncology approaches and advancing research.
The firm has joined forces with AstraZeneca, the IASLC, and the Global Lung Cancer Coalition, with a goal to double five-year survival rates by 2025.
Our first survey of cancer centers around the country shows patients are getting a variety of molecular tests, but only a minority are matching to clinical trials based on the results.
Based on the promising results, the company is advancing the tumor lysate, particle-loaded, dendritic cell vaccine into Phase III studies.